Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal drug therapy for ventricular arrhythmias in Andersen-Tawil syndrome and MEPPC: N-of-1 trials
2024-510682-42-01Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of flecainide in Andersen-Tawil syndrome (ATS) and Multifocal Ectopic Purkinje-related Premature Contractions (MEPPC), sponsored by Amsterdam University Medical Center. Primary endpoint: Ventricular ectopy burden per 24-hour period. Planned start Jun 2024; status: authorised.
02
Drugs
flecainide
03
Conditions
Andersen-Tawil syndrome (ATS)Multifocal Ectopic Purkinje-related Premature Contractions (MEPPC)
Beyond the preview
Go deeper on 2024-510682-42-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510682-42-01.